Literature DB >> 26408064

Surgical History of Sleep Apnea in Pediatric Patients with Chiari Type 1 Malformation.

Isaac Jonathan Pomeraniec1, Alexander Ksendzovsky1, Pearl L Yu1, John A Jane2.   

Abstract

Sleep apnea represents a relative indication for posterior fossa decompression in pediatric patients with Chiari malformation type 1. Duraplasty was associated with improvement of sleep apnea in 100% of patients and dural splitting with improvement in 50% of patients. Duraplasty and dural splitting were associated with a similar reduction in tonsillar herniation on radiographic imaging of 58% (37% excluding tonsillectomy) and 35%, respectively. Longitudinal follow-up studies of patients with either neurologic deficits or severe symptoms will further elucidate the natural history of Chiari malformation type 1 and more appropriately gauge the risk-benefit tradeoff of surgical intervention.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chiari malformation; Dural splitting; Duraplasty; Sleep apnea

Mesh:

Year:  2015        PMID: 26408064      PMCID: PMC4584091          DOI: 10.1016/j.nec.2015.06.009

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  67 in total

1.  Significance of cerebellar tonsillar position on MR.

Authors:  A J Barkovich; F J Wippold; J L Sherman; C M Citrin
Journal:  AJNR Am J Neuroradiol       Date:  1986 Sep-Oct       Impact factor: 3.825

2.  The surgical treatment of Chiari I malformation.

Authors:  J Klekamp; U Batzdorf; M Samii; H W Bothe
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Obstructive sleep apnoea with Arnold-Chiari malformation.

Authors:  M J Doherty; D P Spence; C Young; P M Calverley
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

4.  The effects of posterior fossa decompressive surgery in adult patients with Chiari malformation and sleep apnea.

Authors:  Ricardo Vieira Botelho; Lia Rita Azeredo Bittencourt; José Marcus Rotta; Sérgio Tufik
Journal:  J Neurosurg       Date:  2010-04       Impact factor: 5.115

5.  Outcomes in pediatric patients with Chiari malformation Type I followed up without surgery.

Authors:  David Benglis; Derek Covington; Ritwik Bhatia; Sanjiv Bhatia; Mohamed Samy Elhammady; John Ragheb; Glenn Morrison; David I Sandberg
Journal:  J Neurosurg Pediatr       Date:  2011-04       Impact factor: 2.375

6.  A genetic hypothesis for Chiari I malformation with or without syringomyelia.

Authors:  M C Speer; T M George; D S Enterline; A Franklin; C M Wolpert; T H Milhorat
Journal:  Neurosurg Focus       Date:  2000-03-15       Impact factor: 4.047

7.  Comparison of posterior fossa decompression with or without duraplasty in children with Type I Chiari malformation.

Authors:  Amy Lee; Chester K Yarbrough; Jacob K Greenberg; Jason Barber; David D Limbrick; Matthew D Smyth
Journal:  Childs Nerv Syst       Date:  2014-04-29       Impact factor: 1.475

8.  Position of cerebellar tonsils in the normal population and in patients with Chiari malformation: a quantitative approach with MR imaging.

Authors:  A O Aboulezz; K Sartor; C A Geyer; M H Gado
Journal:  J Comput Assist Tomogr       Date:  1985 Nov-Dec       Impact factor: 1.826

9.  Central sleep apnoea in Arnold-Chiari malformation: evidence of pathophysiological heterogeneity.

Authors:  C Rabec; G Laurent; N Baudouin; M Merati; F Massin; P Foucher; L Brondel; O Reybet-Degat
Journal:  Eur Respir J       Date:  1998-12       Impact factor: 16.671

10.  Snoring, sleep disturbance, and behaviour in 4-5 year olds.

Authors:  N J Ali; D J Pitson; J R Stradling
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

View more
  1 in total

Review 1.  The management of Chiari malformation type 1 and syringomyelia in children: a review of the literature.

Authors:  Veronica Saletti; Mariangela Farinotti; Paola Peretta; Luca Massimi; Palma Ciaramitaro; Saba Motta; Alessandra Solari; Laura Grazia Valentini
Journal:  Neurol Sci       Date:  2021-09-30       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.